Sigma receptor inhibitors
The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
1. A compound which is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride, or another pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound as defined in claim 1 and a pharmaceutically acceptable carrier, adjuvant or vehicle.
3. A method for the manufacture of a medicament comprising combining the compound as defined in claim 1 with a pharmaceutically acceptable carrier, adjuvant or vehicle.
4. A method for the treatment or prophylaxis of a sigma receptor mediated disease or condition, comprising administering to a patient a therapeutically effective amount of the compound as defined in claim 1 , wherein the disease or condition is pain.
5. The method according to claim 4 wherein the disease is neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.